RxDoctor Payments DataLook up a doctor →

Ricardo Tan, MD

Allergy · Los Angeles, CANPI 1255353629

Payments from drug & device makers

$11,223,680in general payments, 2019–2025

Across 1,929 payments — averaging $5818.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$4.4M
  • Novartis$1.3M
  • Teva Pharmaceuticals USA, Inc.$954K
  • Sanofi US Services Inc.$637K
  • GSK$597K
  • AbbVie$482K
  • plus $2.8M from 52 others
$61,326in research payments, 2019–2025

Across 20 payments — averaging $3066.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • E.r. Squibb & Sons, L.L.C.$48K
  • Teva Pharmaceuticals USA, Inc.$10K
  • Regeneron$2K
  • Eli Lilly$1K

What the payments were for

  • Consulting fees$250%
  • Travel & lodging$3,02717%
  • Food & beverage$14,73281%
  • Education$3112%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca114$4,445,850
Novartis87$1,312,532
Teva Pharmaceuticals USA, Inc.200$953,871
Sanofi US Services Inc.88$637,051
GSK135$597,090
AbbVie86$482,436
Astrazeneca UK Limited18$353,197
Amphastar Pharmaceuticals, Inc.3$309,464
Pfizer95$289,368
Sanofi47$261,604
Cipla USA Inc.42$191,281
LEO Pharma AS32$173,897
Genentech, Inc.23$169,054
Regeneron148$160,222
Chiesi USA, Inc.49$144,970
Eli Lilly12$139,881
BD2$124,960
Amgen(2 entities)19$103,522
Galderma Laboratories, L.p.14$85,018
Bayer6$77,462
Incyte Corporation95$57,893
Astrazeneca AB4$44,886
E.r. Squibb & Sons, L.L.C.1$36,470
Dermavant Sciences, Inc.171$28,800
Acrotech Biopharma Inc.5$15,640
Alk-abello, Inc17$9,060
Dr.reddy's Laboratories,inc.1$8,700
Regeneron Healthcare Solutions, Inc.69$1,982
Takeda Pharmaceuticals U.S.A., Inc.76$1,779
CSL Behring81$1,561
Octapharma USA, Inc.26$780
Genentech USA, Inc.41$756
Biocryst US Sales Co., LLC30$681
Grifols USA, LLC14$256
Ionis Pharmaceuticals, Inc.9$200
Optinose US, Inc.9$189
Pharming Healthcare, Inc.5$134
Boehringer Ingelheim5$113
ARS Pharmaceuticals Operations, Inc.5$112
Sanofi-aventis U.S. LLC4$95
Advanced Respiratory, Inc5$92
Mylan Specialty L.p.4$91
Lilly USA, LLC4$90
Kaleo, Inc.3$73
Cycle Pharmaceuticals Inc2$70
Greer Laboratories, Inc.3$68
Shire North American Group Inc3$66
LEO Pharma Inc.3$65
ADMA Biomanufacturing LLC3$46
Philips North America LLC2$30
Tersera Therapeutics LLC1$29
Organon2$26
Blueprint Medicines Corporation1$25
Hikma Pharmaceuticals USA1$21
Bio Products Laboratory USA, Inc.1$19
Aimmune Therapeutics, Inc.1$18
Biocryst Pharmaceuticals, Inc.1$17
Sunovion Pharmaceuticals Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,223,680 in reported general payments places this provider in the 95th percentile of 117 allergy providers in California.

See all allergy providers in California

Medicare billing

Part B allowed, 2024
$133,217
Medicare patients
111
Services billed
4,857

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab15$53,414
Trelegy ElliptaFluticasone/Umeclidin/Vilanter68$50,233
Dupixent SyringeDupilumab12$44,490
Breo ElliptaFluticasone/Vilanterol54$34,762
Atrovent HfaIpratropium Bromide12$6,482
Advair HfaFluticasone Propion/Salmeterol23$6,211
DuleraMometasone/Formoterol13$5,741
Fluticasone-SalmeterolFluticasone Propion/Salmeterol44$4,368
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$3,494
BreynaBudesonide/Formoterol Fumarate17$3,485
Pulmicort FlexhalerBudesonide13$2,900
Albuterol Sulfate HfaAlbuterol Sulfate113$2,750
Mometasone Furoate15$2,425
Epinephrine12$2,292
Wixela InhubFluticasone Propion/Salmeterol21$2,135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$597,090$88,489135 claims
AstraZenecaPulmicort Flexhaler$4,445,850$2,90013 claims
Hikma Pharmaceuticals USAEpinephrine$21$2,29212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 117 allergy providers in California.

Other allergy in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →